Caplin Point Lab Share Price
Caplin Point Lab Share Price Today
As of 22 Jul 2026, Caplin Point Lab share price is ₹2,606.00. The stock opened at ₹2,661.80, compared to its previous close of ₹2,649.20. During today's trading session, Caplin Point Lab share price moved in the range of ₹2,606.00 to ₹2,661.80, with an average price of ₹2,633.90 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,500.30 and a high of ₹2,699.00. On the performance front, Caplin Point Lab share price has increased by 49.95% over the last six months and is up 24.19% on a year-on-year basis.
Caplin Point Lab Returns Calculator
Caplin Point Lab Shareholder Returns
Caplin Point Lab Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,69,382.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,94,375.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,69,333.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,16,447.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Zydus Lifesciences | 1,14,379.00 | 17.39 | 3.23 | 19.69% | 0.35 | 20.30% | 3.70 | 0.11% | 0.39 | 35.38 |
| Lupin | 1,13,316.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,05,979.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 1,02,106.00 | 24.97 | 2.75 | 11.64% | 0.15 | 13.65% | 3.32 | 0.64% | 0.63 | 38.68 |
| Aurobindo Pharma | 90,637.00 | 25.88 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 84,235.70 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Caplin Point Lab Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,937.47 | ₹1,694.10 | ₹1,466.73 | ₹1,269.41 |
| Other Income | ₹96.43 | ₹66.94 | ₹55.98 | ₹38.75 |
| Total Revenue | ₹2,033.90 | ₹1,761.04 | ₹1,522.71 | ₹1,308.16 |
| Total Expenses | ₹1,357.11 | ₹1,196.88 | ₹1,071.44 | ₹922.34 |
| Profit Before Tax | ₹676.78 | ₹564.43 | ₹451.35 | ₹385.82 |
| Tax | ₹135.69 | ₹103.01 | ₹74.36 | ₹77.37 |
| Profit After Tax | ₹541.09 | ₹461.42 | ₹376.99 | ₹308.45 |
| EPS - Basic | ₹70.57 | ₹60.19 | ₹49.62 | ₹39.61 |
| EPS - Diluted | ₹70.25 | ₹59.90 | ₹49.18 | ₹39.26 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹676.78 | ₹564.43 | ₹451.35 | ₹385.82 |
| Income before WC changes | ₹682.29 | ₹566.83 | ₹463.12 | ₹416.27 |
| Change in Assets | -₹117.48 | -₹228.22 | -₹178.01 | -₹95.95 |
| Change in Liabilities | -₹4.80 | ₹88.78 | ₹74.26 | ₹97.91 |
| Change in WC | -₹122.28 | -₹139.44 | -₹103.75 | ₹1.96 |
| Cash flow from Operations | ₹432.37 | ₹318.39 | ₹271.37 | ₹336.73 |
| Cash flow from Investing | -₹334.73 | -₹320.04 | -₹217.58 | -₹376.77 |
| Cash flow from Financing | -₹38.32 | -₹38.07 | -₹28.17 | -₹40.68 |
| Total Cash Flow | ₹59.32 | -₹39.72 | ₹25.62 | -₹80.72 |
| Cash (Start of the year) | ₹138.70 | ₹177.56 | ₹150.76 | ₹231.57 |
| Cash (End of the year) | ₹199.45 | ₹138.70 | ₹177.56 | ₹150.76 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,073.90 | ₹805.20 | ₹639.21 | ₹438.50 |
| Current Assets | ₹2,133.95 | ₹1,892.92 | ₹1,552.19 | ₹1,297.82 |
| Total Assets | ₹3,207.85 | ₹2,698.12 | ₹2,191.40 | ₹1,736.32 |
| Current Liabilities | ₹305.99 | ₹330.85 | ₹268.00 | ₹207.68 |
| Net Current Asset | ₹1,827.96 | ₹1,562.07 | ₹1,284.19 | ₹1,090.14 |
| Non-Current Liabilities | ₹15.47 | ₹20.44 | ₹16.13 | ₹18.76 |
| Equity Capital | ₹2,886.39 | ₹2,346.83 | ₹1,907.27 | ₹1,509.88 |
| Total Equity & Liabilities | ₹3,207.85 | ₹2,698.12 | ₹2,191.40 | ₹1,736.32 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹752.41 | ₹625.09 | ₹528.61 | ₹528.06 |
| Other Income | ₹134.59 | ₹105.84 | ₹99.00 | ₹56.55 |
| Total Revenue | ₹887.00 | ₹730.93 | ₹627.61 | ₹584.61 |
| Total Expenses | ₹445.33 | ₹365.19 | ₹334.46 | ₹334.30 |
| Profit Before Tax | ₹441.67 | ₹365.74 | ₹293.15 | ₹250.31 |
| Tax | ₹102.18 | ₹82.03 | ₹58.89 | ₹62.44 |
| Profit After Tax | ₹339.49 | ₹283.71 | ₹234.26 | ₹187.87 |
| EPS - Basic | ₹44.67 | ₹37.36 | ₹30.89 | ₹24.82 |
| EPS - Diluted | ₹44.67 | ₹37.18 | ₹30.62 | ₹24.60 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹441.67 | ₹365.74 | ₹293.15 | ₹250.31 |
| Income before WC changes | ₹357.20 | ₹297.17 | ₹233.58 | ₹230.88 |
| Change in Assets | -₹36.74 | -₹74.52 | -₹54.85 | ₹40.27 |
| Change in Liabilities | -₹20.75 | -₹24.55 | ₹43.41 | ₹21.80 |
| Change in WC | -₹57.49 | -₹99.07 | -₹11.44 | ₹62.07 |
| Cash flow from Operations | ₹195.87 | ₹111.01 | ₹157.10 | ₹230.97 |
| Cash flow from Investing | -₹140.20 | -₹118.94 | -₹86.67 | -₹275.93 |
| Cash flow from Financing | -₹38.10 | -₹34.26 | -₹30.42 | -₹22.76 |
| Total Cash Flow | ₹17.57 | -₹42.19 | ₹40.01 | -₹67.72 |
| Cash (Start of the year) | ₹80.64 | ₹122.02 | ₹81.01 | ₹148.82 |
| Cash (End of the year) | ₹99.64 | ₹80.64 | ₹122.02 | ₹81.01 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹988.79 | ₹819.21 | ₹641.48 | ₹448.49 |
| Current Assets | ₹825.69 | ₹703.10 | ₹661.70 | ₹605.67 |
| Total Assets | ₹1,814.48 | ₹1,522.31 | ₹1,303.18 | ₹1,054.16 |
| Current Liabilities | ₹99.85 | ₹118.87 | ₹146.85 | ₹98.88 |
| Net Current Asset | ₹725.84 | ₹584.23 | ₹514.85 | ₹506.79 |
| Non-Current Liabilities | ₹13.70 | ₹13.29 | ₹16.42 | ₹24.63 |
| Equity Capital | ₹1,700.93 | ₹1,390.15 | ₹1,139.91 | ₹930.65 |
| Total Equity & Liabilities | ₹1,814.48 | ₹1,522.31 | ₹1,303.18 | ₹1,054.16 |
About Caplin Point Lab
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Caplin Point Lab Financial Highlights
- Revenue: Caplin Point Lab reported revenue of ₹2,302.73 crore in FY26 vs ₹2,033.90 crore in FY25. It showed an increase of 13.22% on a yearly basis.
- Operating Profit: Caplin Point Lab reported an operating profit of ₹802.79 crore in FY26 vs ₹676.78 crore in FY25. It showed an increase of 18.62% on a year-on-year basis.
- Net Profit: Caplin Point Lab reported a net profit of ₹649.73 crore in FY26 vs ₹541.09 crore in FY25. It showed an increase of 20.08% on a yearly basis.
Caplin Point Lab Quarterly Result Highlights
- Caplin Point Lab reported revenue of ₹628.52 crore in Mar 2026, compared with ₹576.45 crore in Dec 2025, representing an increase of 9.03% on a quarter-on-quarter (QoQ) basis.
- Caplin Point Lab reported an operating profit of ₹213.44 crore in Mar 2026, compared with ₹203.89 crore in Dec 2025, representing an increase of 4.68% on a quarter-on-quarter (QoQ) basis.
- Caplin Point Lab reported a profit of ₹172.88 crore in Mar 2026, compared with ₹165.86 crore in Dec 2025, reflecting an increase of 4.23% on a QoQ basis.
- The earnings per share (EPS) of Caplin Point Lab stood at ₹70.57 during Mar 2026.
Similar Stocks
FAQs on Caplin Point Lab Share Price
What is Caplin Point Lab share price today?
Caplin Point Lab share price is ₹2,606.00 as on 21 Jul, 2026, 15:29 IST.
How has the Caplin Point Lab share price performed in the past?
In the last 1 year, Caplin Point Lab delivered a return of 24.19%. The Caplin Point Lab share price hit a high of ₹2,699.00 and low of ₹1,500.30.
How much is the Mutual Fund shareholding in Caplin Point Lab shares?
The Mutual Fund Shareholding in Caplin Point Lab was 2.02% at the end of Mar 2026.
What is the the 52-week high and low of Caplin Point Lab shares ?
The 52-week high and low of Caplin Point Lab share is ₹2,699.00 and ₹1,500.30 as of 21 Jul, 2026.
What is the market cap of Caplin Point Lab?
The market capitalisation of Caplin Point Lab is ₹20,126.00 Crores as on 21 Jul, 2026.
What are the stock symbols of Caplin Point Lab?
The stock symbol of Caplin Point Lab is CAPLIPOINT on the NSE, 524742 on the BSE, and the ISIN is INE475E01026.
What was yesterday's closing price of Caplin Point Lab shares ?
Caplin Point Lab shares closed yesterday at ₹2,649.20 on NSE & ₹2,647.75 on BSE
How to buy Caplin Point Lab shares?
To buy Caplin Point Lab shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Caplin Point Lab shares on Holidays?
No, shares of Caplin Point Lab or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Caplin Point Lab shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Caplin Point Lab?
The PE and PB ratio of Caplin Point Lab is 30.5 and 5.53 respectively, as on 21 Jul, 2026, 15:29 IST.